Cancer Health Treatment Update
Ibrance Slows Progression of Double-Positive Metastatic Breast Cancer

Addition of the CDK 4/6 inhibitor improved progression-free survival by 15.2 months for patients with HR-positive/HER2-positive advanced breast cancer.

Program Targets Poverty to Improve Childhood Cancer Treatment
Children from low-income households are more likely to experience cancer relapse and face lower survival rates compared to their more privileged peers.
FDA Approves Ensacove for ALK-Positive Advanced Non-Small Cell Lung Cancer

Ensartinib, an oral targeted therapy, improved progression-free survival for patients with locally advanced or metastatic NSCLC.

Cancer Health Winter 2025
Check out our new print edition!
Advertisement
News From SABCS 2024

News about the latest research on breast cancer biology, prevention and treatment from the San Antonio Breast Cancer Symposium.

News From ASH 2024

Blood cancer news from the American Society for Hematology Annual Meeting and Exhibition.

NIH Adds Funds to Long COVID-19 Research, Advances Work on New Clinical Trials

Federal agency will reallocate $147 million to support the NIH RECOVER Initiative, focusing on developing long COVID treatments.

More News About COVID-19
See all our coverage of COVID-19, including how it affects people living with cancer. For more news about SARS-CoV-2, visit our sister site, COVIDHealth.com.

You are receiving this email because you opted in at one of our websites. At your request, this message was sent to newsletter@newslettercollector.com by update@cancerhealth.com. Please remember to add update@cancerhealth.com to your email address book, so that these updates aren't blocked as spam.

To change your subscription information and preferences, please visit your personal preferences page. Or you can unsubscribe completely from this list.

To forward this message, please do not use the forward button of your email application, because this message was made specifically for you only. Instead use the forward page in our newsletter system.

Did you receive this email from a friend? You can subscribe and you will receive our next newsletter directly to your inbox.

Our mailing address is:

Smart + Strong
157 Columbus Avenue, Suite 525
New York, NY 10023

Add us to your address book

Copyright (C) 2024 Smart + Strong 157 Columbus Avenue, Suite 525 New York, NY 10023 USA All rights reserved.
Terms Of Use and Your Privacy.